Investor Presentation

November 05, 2026 To, To, The Listing Department, The Listing Department BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai – 400001 Mumbai – 400051 Scrip code: 544889 Symbol: SYMBIOTEC Sub: Investor Presentation - Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“SEBI Listing Regulations”) Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI Listing Regulations, please find enclosed Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. The aforesaid disclosure is also available on the Company’s website at https://investor.symbiotec.com/financials?tab=presentations This is for your Information and Records. Thanking you, For Symbiotec Pharmalab Limited Salil Jain Company Secretary & Compliance Officer Membership No. A41610 Encl.: As above Registered Office & Works: Symbiotec Pharmalab Limited (Formerly known as Symbiotec Pharmalab Pvt. Ltd.) 385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222, Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com CIN: U24232MP2002PLC015293 Symbiotec Pharmalab Limited Q2 & H1FY27 Investor Presentation November 2026 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Symbiotec Pharmalab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Q2 & H1FY27 Performance Highlights Management Commentary Commenting on Q2FY27 performance, Mr. Anil Satwani, Chairman & Managing Director of Symbiotec Pharmalab Limited, said: “Our Q2 FY27 performance reflects strong business momentum, underpinned by the continued progress of our core business and the scaling up of our emerging growth engines. Our API business continues to deliver steady revenue growth of 11% Y-o-Y in H1FY27, driven by healthy volume growth and a favourable product mix. This strong performance in our core business provides a solid foundation as we continue to pursue new opportunities and expand into adjacent growth segments. During the quarter, we signed a Licensing agreement for distribution of two DCV products in the US, for certain completed milestones we have partly recognized revenues in Q2 FY27 and the rest expected to be recognized in the upcoming quarters. Commercial supplies are expected to commence next year, providing an additional boost to our revenue and profitability. We remain committed to investing in further product development and regulatory filings to Anil Satwani strengthen our presence in this space of Complex injectables. Chairman & Managing Director In our CDMO business, the signing of a 10 year take-or-pay agreement with a Europe-based company in the alternative protein space is at an advanced stage. This potential agreement enables us to significantly expand our bio- manufacturing capacity in a phased manner, aligned with customer requirements and demand visibility. Overall, we remain confident in our growth outlook and the potential of our emerging businesses. We believe our Injectables and CDMO businesses have the potential to scale meaningfully over the coming years and ultimately reach a size comparable to our established API business.” H1FY27 Key Business Updates APIs Products Complex Injectables CDMO Services ✓ Sales growth steady at 11% in ✓ Licensing agreement for distribution ✓ Industrial Biotech : H1FY27 of two DCV products in US o 10 years take-or-pay agreement with US ✓ Successfully completed 4 major o Agreement signed based Alternate Protein player in place regulatory audits recently: o Completed milestones invoiced & part • Project capex on track. revenue of Rs. 53 crs recognized in Q2 o EUGMP audits in Rau and Pithampur o 10 years take-or-pay term sheet with plants in Mar 2026 ✓ First molecule ANDA for DCV filed Europe based Alternate Protein player - agreement signing in advanced stage • Approval certification received for and accepted by USFDA successfully both plants • Initial manufacturing to commence in o First generic filing for the DCV product o USFDA audits in H1FY27 at Rau & in US market Pithampur plants ✓ Pharmaceutical : Insulin Drug ✓ Filing of second ANDA scheduled for Substance (DS) • EIR received for both plants Q4 FY27 o 5 years take-or-pay agreement in place, o Pre-submission Facility Correspondence Capex on track (PFC) submitted qualifying for expedited Priority Review • Filing regulatory approval in Q4 FY27 / Q1 FY28 Q2 & H1FY27 Financial Highlights Consol Revenue (Rs. in Crs) Consol EBITDA* (Rs. in Crs) Consol PAT (Rs. in Crs) New Businesses in H1 : 26% 34% 27% 28% 10% 19% 12% 13% o Milestone revenue – Rs. 53 crs o Opex - Rs. 57 crs including +25% +29% +34% +169% ANDA filing fees 498 +88% 140 66 o Depreciation – Rs. 24 crs +43% 399 108 52 280 *EBITDA adjusted for One-time 196 50 impact of Rs. 3 crs towards IPO listing expenses debited to P&L Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 API Revenue (Rs. in Crs) API EBITDA (Rs. in Crs) Steady API Business +11% +15% ➢ API Gross margins upwards of 60% 442 137 +16% +21% ➢ API EBITDA margins at ~30% driven by 227 71 196 59 revenue growth and favourable sales mix Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Margin [Showing first 8,000 characters — download PDF for full document]